Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) Net Margin: 2012-2025

Historic Net Margin for Sunshine Biopharma (SBFM) over the last 12 years, with Sep 2025 value amounting to 3.14%.

  • Sunshine Biopharma's Net Margin rose 1734.00% to 3.14% in Q3 2025 from the same period last year, while for Sep 2025 it was -16.06%, marking a year-over-year increase of 66.00%. This contributed to the annual value of -14.72% for FY2024, which is 398.00% up from last year.
  • Sunshine Biopharma's Net Margin amounted to 3.14% in Q3 2025, which was up 110.02% from -31.36% recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Net Margin registered a high of 783.75% during Q4 2021, and its lowest value of -15,440.43% during Q1 2021.
  • Over the past 3 years, Sunshine Biopharma's median Net Margin value was -16.28% (recorded in 2023), while the average stood at -17.50%.
  • In the last 5 years, Sunshine Biopharma's Net Margin tumbled by 1,459,140bps in 2021 and then spiked by 1,443,245bps in 2022.
  • Sunshine Biopharma's Net Margin (Quarterly) stood at 783.75% in 2021, then crashed by 138,054bps to -596.78% in 2022, then surged by 58,051bps to -16.28% in 2023, then plummeted by 622bps to -22.49% in 2024, then soared by 1,734bps to 3.14% in 2025.
  • Its last three reported values are 3.14% in Q3 2025, -31.36% for Q2 2025, and -13.25% during Q1 2025.